The public cloud has become a key facilitator for meeting new demands as a result of the coronavirus pandemic. This has been especially true for the pharmaceutical sector in which multibillion-dollar companies race to cultivate therapies to treat complications and comorbidities associated with COVID-19, as well as vaccines.
Takeda Pharmaceutical, which make medicines that treat some cancers, diabetes and hypertension, is teaming with Amazon Web Services on a five-year deal to move 80 percent of its applications to AWS’s public cloud. Takeda plans to use AWS to boost its R&D pipeline for drug discovery and to create new business capabilities, while eliminating on-premises technology and expenditures that don’t help differentiate the company from its rivals, Takeda CIO Karl Hick tells CIO.com.
To read this article in full, please click here
(Insider Story)
Read More from This Article: Takeda and AWS accelerate COVID-19 research push
Source: News